Actuate Therapeutics (NASDAQ:ACTU) Issues Earnings Results

Actuate Therapeutics (NASDAQ:ACTU) posted its earnings results on Thursday. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01), Zacks reports.

Actuate Therapeutics Stock Performance

ACTU stock traded down $0.07 on Thursday, hitting $2.90. 35,436 shares of the company’s stock were exchanged, compared to its average volume of 114,396. The stock has a market cap of $68.76 million, a P/E ratio of -2.76 and a beta of 0.92. Actuate Therapeutics has a 12-month low of $1.58 and a 12-month high of $11.99. The firm has a 50 day moving average price of $2.58 and a two-hundred day moving average price of $4.72.

Analysts Set New Price Targets

ACTU has been the topic of a number of analyst reports. Wall Street Zen upgraded Actuate Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Friday, March 27th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Actuate Therapeutics in a research report on Wednesday, April 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $17.50.

Institutional Trading of Actuate Therapeutics

Several large investors have recently bought and sold shares of ACTU. Deutsche Bank AG grew its position in Actuate Therapeutics by 640.0% during the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock worth $57,000 after purchasing an additional 8,051 shares during the last quarter. Barclays PLC raised its stake in shares of Actuate Therapeutics by 68.6% in the fourth quarter. Barclays PLC now owns 14,946 shares of the company’s stock worth $91,000 after purchasing an additional 6,081 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Actuate Therapeutics by 61,068.0% in the second quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock worth $93,000 after purchasing an additional 15,267 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Actuate Therapeutics in the fourth quarter worth about $102,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Actuate Therapeutics in the second quarter worth about $105,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.